Ginkgo Bioworks Holdings (DNA) Total Debt (2020 - 2021)
Ginkgo Bioworks Holdings' (DNA) quarterly Total Debt came in at $631638.0 in Q2 2021, up 304.03% on a QoQ basis from $156333.0 in Q4 2020.
Ginkgo Bioworks Holdings (DNA) Total Debt (2020 - 2021) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 2 years of Total Debt data on file, last reported at $631638.0 in Q2 2021.
- Quarterly Total Debt changed N/A year-over-year to $631638.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $631638.0 (changed N/A YoY) and the FY2020 annual result came in at $156333.0, changed N/A from the prior year.
- Total Debt rose to $631638.0 in Q2 2021, from $156333.0 in the prior quarter.
- In the past five years, Total Debt ranged from a high of $631638.0 in Q2 2021 to a low of $156333.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 631,638.00 |
| Dec 31, 2020 | 156,333.00 |